Treatment of advanced stage Hodgkin's disease

Oncology

Volumn 60, Issue 2, 2001, Pages 101-109

  Tesch, H ^a,b   Sieber, M ^a   Diehl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SCHWARZWALD BAAR KLINIKUM   (Germany)

Author keywords

Chemotherapy; Hodgkin's disease; Radiotherapy

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LEUKEMIA; ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; REPRODUCTIVE TOXICITY; REVIEW; SECOND CANCER; STEM CELL TRANSPLANTATION; THYROID DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MECHLORETHAMINE; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; VINBLASTINE; VINCRISTINE;

EID: 0035077111     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055305     Document Type: Review

References (43)

1. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia
2. Combination chemotherapy in the treatment of advanced Hodgkin's disease
3. Hodgkin's disease
4. Twenty years of MOPP therapy for Hodgkin's disease
5. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results
6. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: A cooperative study by the Cancer and Leukemia Group B
7. BCVPP chemotherapy for advanced Hodgkin's disease: Evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study
8. Combination chemotherapy in generalized Hodgkin's disease
9. MVPP chemotherapy regimen for advanced Hodgkin's disease
10. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease
11. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
12. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy
13. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
14. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
15. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute
16. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
17. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
18. Comparison of Adriamycin-containing chemotherapy (MOP-BAP) with MOPP-bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study
19. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results
20. Rapidly alternating COPP + ABV + IMEP (CAI) is equally effective as alternating COPP + ABVD (CA) for Hodgkin's disease: Final results of two randomised trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages
21. Review of etoposide single-agent activity
22. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update
23. Preliminary results of a four-centre randomised trial comparing weekly VAPEC-B chemotherapy with the ChlVPP/EVA hybrid regimen in previously untreated patients
24. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy
25. Randomized comparison of COPP/ABVD vs. dose and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease
26. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease
27. Dose-escalation study for the treatment of Hodgkin's disease
28. BEACOPP: A new regimen for advanced Hodgkin's disease
29. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
30. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients
31. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
32. Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy
33. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol
34. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy
35. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis
36. The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission
37. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease?
38. A prognostic score for advanced Hodgkin's disease
39. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals
40. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study
41. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease
42. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease
43. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial